In normal and diseased vascular smooth muscle (SM), the RhoA pathway, which is activated by multiple agonists through G protein-coupled receptors (GPCRs), plays a central role in regulating basal tone and peripheral resistance. This occurs through inhibition of myosin light chain phosphatase, leading to increased phosphorylation of the myosin regulatory light chain. Although it is thought that specific agonists and GPCRs may couple to distinct RhoA guanine nucleotide exchange factors (GEFs), thus raising the possibility of selective targeting of specific GEFs for therapeutic use, this notion is largely unexplored for SM contraction.
T he contractile response in smooth muscle (SM) to agonist stimulation is mediated through the phosphorylation of the myosin regulatory light chain (RLC 20 ) . The level of this phosphorylation reflects the balance of the opposing activities of the calcium-calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain phosphatase. [1] [2] [3] Although an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ]) serves as a primary on-switch for the activation of MLCK, both MLCK and myosin light chain phosphatase are additionally regulated by diverse kinases, which in turn are regulated by diverse physiological agonists. 3, 4 Importantly, the activity of myosin light chain phosphatase is negatively regulated when Thr853, located in its regulatory, myosin targeting phosphatase subunit (MYPT1) is phosphorylated by the Rho-kinase (ROCK). [1] [2] [3] This inhibition of myosin light chain phosphatase activity results in an increase in force generating phosphorylated myosin motors, without further increase in intracellular [Ca 2ϩ ]. This physiologically important phenomenon is known as Ca 2ϩ sensitization. 3, [5] [6] [7] The Ca 2ϩ sensitization pathway is initiated when ROCK is activated by the GTP-bound, biologically active form of the cytosolic GTPase, RhoA. 8 Like other GTPases of the Ras-homology (Rho) family, 9, 10 RhoA functions as a molecular switch; it is biologically inert in the GDP-bound form, but on exchange of GDP to GTP, it undergoes a conformational change enabling it to interact with various target effectors. [11] [12] [13] This results, for example, in the activation of kinases, such as ROCK. RhoA can serve as a switch, because it is a poor hydrolase, with k cat of Ϸ1/min, 14 and can therefore exist for considerable time period as a substrate-enzyme complex (the on-state). To switch between the on-and off-states, RhoA is therefore assisted by other regulatory proteins in its catalytic cycle. The GTPase-activating proteins enhance the hydrolysis of GTP to GDP, 15, 16 thereby terminating the biological signal. The GDP-bound RhoA is then sequestered in the cytosolic pool by the Rho-nucleotide dissociation inhibitor, RhoGDI. [17] [18] [19] Finally, a family of guanine nucleotide exchange factors (GEFs) catalyze the loading of GTP for GDP, reinitiating the signaling cycle. 20 Both GTPaseactivating proteins and GEFs are themselves tightly regulated upstream of RhoA.
Basal tone and the contractile state of SM are regulated by multiple agonists acting through G-protein coupledreceptors (GPCRs) leading to a rise in intracellular [Ca 2ϩ ]. However, the magnitude of force at a specific level of [Ca 2ϩ ] is highly variable depending on the nature of the stimulus and on the vascular bed. In cases in which the force/ [Ca 2ϩ ] ratio is high, the force is enhanced due to the activation of a RhoA/ROCK signaling pathway, and consequently Ca 2ϩ sensitization. Thus, diverse agonists acting on heterotrimeric GPCRs can exert different magnitudes of RhoA-mediated [Ca 2ϩ ]-sensitized contractile force. 3, [21] [22] [23] This strongly suggests the presence of coupling in SM between agonist-activated GPCRs and RhoA, most likely through different GEFs. However, it is not clear how many RhoA-specific GEFs are functional in SM, whether specific GEFs are coupled to specific agonists and GPCRs, or if they regulate different functions in SM cells.
Consistent with the notion that specific agonists and GPCRs couple to specific RhoGEFs, a small family of GEFs was recently found to be activated directly by G␣ 12/13 -coupled receptors. 24, 25 These proteins contain a unique RGSL (regulator of G-protein signaling-like) domain, which recognizes and binds to G␣ 12/13 . 26 -28 It has been demonstrated that one of these GEFs, the leukemiaassociated RhoGEF (LARG) 29 plays a central role in the regulation of vascular SM tone in salt-dependent hypertension but not in the maintenance of basal blood pressure. 30 The other 2 related RGSL-containing GEFs, PDZRhoGEF protein 31, 32 and p115-RhoGEF, 33 were also found in SM tissues, but whether they couple to specific or multiple agonists and GPCRs is unknown.
Agonist coupling through GPCRs to G␣ q/11 is thought to be involved in the stimulation of phospholipase C (PLC)-mediated, Ca 2ϩ -calmodulin activation of MLCK 3, 22, 34, 35 and activation of RhoA. 35, 36 It has been shown that the RhoA-specific GEF, p63RhoGEF, 37, 38 is involved in SM signaling in response to stimulation by angiotensin II. 35 In this report, we present evidence for the involvement of p63RhoGEF specifically in mediation of G␣ q/11 -coupled, agonist-induced Ca 2ϩ -sensitized force in SM. We determined that p63RhoGEF mRNA and protein is ubiquitously present in SM cells and in vascular and gastrointestinal tissue across several species, including the human. We further show that after stimulation through G␣ q/11 with agonists such as endothelin-1 (ET-1) and phenylephrine, p63RhoGEF catalyzes GTP exchange on RhoA in SM and regulates Ca 2ϩ sensitization.
Methods
All procedures using animals were carried out according to protocols approved by the Animal Care and Use Committee at the University of Virginia. Detailed experimental procedures are in Supplemental Material available at http://circres.ahajournals.org.
Anti-p63RhoGEF Antibodies
Two anti-p63RhoGEF antibodies were purchased from Proteintech, Illinois (51004 -1-AP and 14839 -1-AP).
Expression Plasmids and Recombinant Protein Production
Human p63RhoGEF cDNA was PCR-amplified and introduced into pGST-Parallel1, 39 p3xFLAG-Myc-CMV-24 (SIGMA), and pcDNA3 (Invitrogen) plasmids. Glutathione S-transferase (GST)-fused p63RhoGEF 331-580 recombinant protein was produced in Escherichia coli BL21 and purified using glutathione beads. GST was subsequently cleaved off using recombinant tobacco etch virus (TEV) protease.
SM Contraction Experiment
Force measurements on intact, ␣-toxin, or ␤-escin permeabilized muscles were carried out as detailed in the Supplemental Material.
Rhotekin Assay
Rabbit portal vein strips were prepared and treated using the same protocols as in the contraction experiments and harvested at each critical time point. Mouse embryonic fibroblast (MEF) cells were transfected with mammalian expression plasmids to overexpress FLAG-p63RhoGEF . RhoA activity was assayed as detailed in the Supplemental Material.
RLC 20 and MYPT1 Phosphorylation
Rabbit portal vein strips were treated using the same protocols as in the contraction assays and processed as described previously. 40 Phosphorylation measurements are detailed in the Supplemental Material.
Coimmunoprecipitation Assays
Coimmunoprecipitation assays on human embryonic kidney (HEK) 293 cell transfectants (expressing combinations of FLAGp63RhoGEF-Full-Myc and/or FLAG-p63RhoGEF
331-580 and/or G ␣11 wild-type or G ␣11 Q209T constitutively active mutant) are detailed in the Supplemental Material.
p63RhoGEF Knock-Down
An RNA interference sequence [GCCAAGCTGGATGAAGAT-GAG] was designed to target both mouse and human p63RhoGEF mRNAs that coincidentally match rat p63RhoGEF mRNA sequence. Short hairpin RNA (shRNA) was delivered and expressed either by pENTR/U6 plasmid (Invitrogen) or adenovirus including the sequence for the expression of shRNA in mammalian cells.
Quantitative Polymerase Chain Reaction
Total mRNA libraries prepared from unpassaged aortic, pulmonary artery and brain vascular SM primary human cell cultures were purchased from ScienCell Research Laboratories (Carlsbad, CA). RNA was also prepared from animal tissue samples. mRNA expression levels of p63RhoGEF and other GEFs were quantified by RT-PCR.
Statistical Analysis
All data are presented as meanϮSEM. Differences were considered significant at a probability value Ͻ0.05 using 2-tailed Student t test.
Results p63RhoGEF Transcription and Expression in SM
We chose the mouse as our principal model system. To quantify the level of p63RhoGEF transcription in comparison to those of other GEFs in mouse SM, we performed quantitative RT-PCR using mouse vascular SM tissues. To assess if the transcription patterns are representative of those observed in human, we also screened mRNA libraries from human aorta, pulmonary artery, and brain vascular primary, unpassaged SM cells. The p63RhoGEF mRNA was detected in all of the mouse tissues screened and showed particularly high transcription levels in portal vein ( Figure 1 )-which was subsequently used in our functional assays-as well as in aorta and pulmonary artery. Of significance is the presence of p63RhoGEF mRNA in mouse resistance arteries, such as the thoracodorsal and mesenteric arteries. In human cells, p63RhoGEF mRNA level was the highest in the aorta, followed by pulmonary artery and brain vascular SM cells (Figure 1, inset) .
To assess the expression levels of p63RhoGEF we turned to rat tissues, because of the larger body size of the animal. As shown in Figure 2 , p63RhoGEF was detected in diverse tissues, except for brain, liver, diaphragm, and heart. Similar results were obtained for select mouse and rabbit tissues indicating a consistent trend across species (data not shown). Importantly, we also screened rat tissues for the expression of G␣ q/11 , and we discovered that it follows a trend similar to p63RhoGEF. Similarly, RhoA expression was high in SM ( Figure 2 ). Expression of p63RhoGEF was also detected in cultured rat aortic SM cells (R518) and mouse embryonic fibroblast (MEF) cells ( Figure 2 ) but not in human embryonic kidney (HEK) 293 cells (Online Figure I, B) . The anti-p63RhoGEF antibody typically gave triplet bands across species by Western blot and the lowest molecular weight band is predominant in mouse samples and is demonstrated to be nonspecific (Online Figure I , B). The top band (80 kDa) corresponds to the full-length p63RhoGEF consisting of 580 amino acid residues. Further details of experiments characterizing the p63RhoGEF antibodies and showing that the lowest band is nonspecific while the middle band probably is a truncated form of p63RhoGEF are described in the Supplemental Material. Although the presence of p63RhoGEF mRNA in brain and heart 38, 41 and HEK293 cells 37 has been reported previously, we only observed the lowest protein molecular weight band in brain samples ( Figure 2 ).
Suppression of Mouse Portal Vein Contractility by p63RhoGEF Knock-Down
Next, we asked if knock-down of p63RhoGEF might suppress contractility in intact blood vessels. Using LacZexpressing adenovirus, we found that we can successfully infect mouse portal veins and cerebral vessels but not the aorta or mesenteric arteries. Therefore, we treated mouse portal veins with a viral construct designed to express short hairpin RNA (shRNA) targeting p63RhoGEF mRNA. This construct was effective as it knocked down the protein expression of p63RhoGEF by up to 79% in cultured cells (Online Figure I, A) . In portal vein, after 5 days of treatment with the viral particle, the p63RhoGEF mRNA was reduced by 40%, based on quantitative RT-PCR analysis ( Figure 3A ). Reduction of p63RhoGEF at the protein level by Ϸ35% was confirmed by Western blot analysis, using 2 pooled mouse portal veins ( Figure 3A ). Similar effects were also observed in 3 other Western blot analyses using the same portal vein SM strips used in contraction experiments, although the small sample size did not allow accurate quantification (data not shown).
To probe the impact of the p63RhoGEF knock-down on G␣ q/11 and G␣ 12/13 -mediated SM contractility, we used, respectively, endothelin-1 (ET-1) and a thromboxane analog U46619 as agonists. The ET-1 receptor is coupled to G␣ q/11 , whereas U46619 acts primarily through G␣ 12/13 . Both agonists induce strong contractile responses in intact SM through a combination of Ca 2ϩ influx, Ca 2ϩ -dependent activation of PLC, Ca 2ϩ release from intracellular compartments, as well as Ca 2ϩ sensitization. 42, 43 Contraction in response to increasing concentrations of ET-1 was significantly lower in p63RhoGEF shRNAtreated vessel strips compared with control (nontargeting) treated vessels ( Figure 3B , Online Figure II) . Contraction induced by U46619 in shRNA-treated vessels was only slightly lower at the higher concentrations of U46619, than that observed in control treated vessels, although the difference did not reach statistical significance ( Figure 3C and Online Figure II Having established a link between p63RhoGEF and SM contractility in response to ET-1, we set out to examine the effect of reduced p63RhoGEF levels specifically on the RhoA-mediated, Ca 2ϩ sensitization pathway. To assess contractility in the absence of Ca 2ϩ influx, Ca 2ϩ release from intracellular compartments, and other [Ca 2ϩ ]-dependent phenomena, we studied contractile activity of mouse portal vein permeabilized to ions by ␣-toxin at a constant buffered intracellular [Ca 2ϩ ], a protocol that retains receptor-coupling to RhoA. 3, 6 Contraction induced by stimulation with ET-1 at pCa 6.3 was significantly reduced in vessels in which p63RhoGEF expression was reduced, when compared with nontargeting control treated vessels ( Figure 4A through 4C). Subsequent addition of GTP␥S (10 mol/L), as a means to activate RhoA directly bypassing GEF function, resulted in significantly increased contractile responses in vessels where p63RhoGEF expression was reduced ( Figure 4A and 4B). This is consistent with lower levels of activated, GTP-bound RhoA in the knocked-down vessels. In contrast, the U46619 contractile responses of nontargeting and p63RhoGEF shRNA-treated vessels did not differ significantly. The maximal contraction at pCa 4.5, expressed as absolute force, was not affected by knock-down of p63RhoGEF, as evidenced by identical maximal force from identical sizes of vessel strips of the two samples (0.10Ϯ0.03 versus 0.10Ϯ0.02 mN). Importantly, phosphorylation of MYPT1 at the ROCK target, Thr853 after stimulation with ET-1 was significantly reduced in the p63RhoGEF shRNA-treated portal vein, as compared with controls ( Figure 4D ), consistent with a reduction in RhoA activity. In contrast, MYPT1 Thr853 phosphorylation was not significantly changed in vessels stimulated with U46619 ( Figure 4D ).
Ca

2؉ Sensitized Force Is Relaxed by the Recombinant Extended PH Domain Fragment of p63RhoGEF
It has been established that in its nascent form, p63RhoGEF is autoinhibited. The molecule contains a Dbl-homology (DH domain), a minimal unit to catalyze the GTP exchange reaction, 20, 44 and an adjacent C-terminal pleckstrin-homology (PH) domain, which exerts an autoinhibitory function through an interaction with the DH domain. This mechanism appears to be conserved in the related Dbl family members, Trio and Kalirin. 45 Activation occurs when the G␣ q/11 subunit binds to specific amino acids in the PH domain plus its adjacent conserved amino acid stretch (extended PH domain) of p63RhoGEF, thus causing a structural reorganization in p63RhoGEF and relief of autoinhibition. We hypothesized that if the Ca 2ϩ -sensitization effect is mediated by the same mechanism, then the isolated, recombinant extended PH domain (p63RhoGEF ) should interfere with the process, either by binding to the activated G␣ q/11 and blocking downstream signaling, or by binding to the transiently open, that is, active conformation of endogenous p63RhoGEF. To test this hypothesis in intact blood vessels, we needed a vessel that responds to phenylephrine and can be well permeabilized to proteins to allow for the introduction of the p63RhoGEF fragment into the SM cells, while retaining the receptor-coupling to RhoA. Because this was not possible using mouse portal vein, we used instead rabbit portal vein permeabilized with 
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␤-escin. 46 Fortuitously, unlike the mouse vessel, rabbit portal vein responds to phenylephrine, reported to act purely through G␣ q/11 and not G␣ 12/13 , 30 with Ca 2ϩ sensitized force at constant intracellular [Ca 2ϩ ] (pCa 6.3). Phenylephrine/G␣ q/11 coupling was established in mouse aorta. 30 Phenylephrine is a specific ␣1-adrenoreceptor agonist 47 shown to specifically mediate contractile responses through activation of G␣ q/11 . 48 ␣1-Adrenoreceptors have been shown to be present and functional in rabbit arteries including the carotid, aortic, iliac, mesenteric, renal, ear, and resistance arteries. 47 Therefore, we assume that they are also present in rabbit portal vein. Additionally, this vessel contracts in response to phenylephrine. When the contractile force induced by phenylephrine reached a plateau, a control filtrate (ie, buffer from which recombinant p63RhoGEF 331-580 protein was removed) was added, followed by the p63RhoGEF 331-580 protein. The filtrate produced no effect ( Figure 5A ), whereas the recombinant p63RhoGEF 331-580 fragment induced relaxation of the SM strips ( Figure 5A ; Online Figure III ). Both RhoA activity and RLC 20 phosphorylation level increased with phenylephrine-induced Ca 2ϩ sensitized force and both decreased on introduction of p63RhoGEF (Figure 5B) . These findings in blood vessels confirm the hypothesis that recombinant p63RhoGEF 331-580 inhibits endogenous p63RhoGEF or interferes with the regulatory pathway by sequestering activated G␣ q/11 as predicted from in vitro experiments. 45 
RhoA-GDP Turnover Is Suppressed in MEF Cells by Overexpression of p63RhoGEF 331-580 Fragment
Having established an inhibitory role for p63RhoGEF in blood vessels, we investigated if it acts in the same way in cells. We could not use SM cells for that purpose because their transfection efficiency is generally only Ͻ2% to 3% by traditional methods and about 30% by electroporation. Instead, we resorted to mouse embryonic fibroblasts (MEF), in which we were able to achieve 80% transfection efficiency. Using MEF cells we investigated the changes in relative levels of RhoA•GTP on phenylephrine stimulation in the presence and absence of exogenous p63RhoGEF . RhoA•GTP levels were increased when MEF cells were stimulated by phenylephrine (5 mol/L) ( Figure 6A ), and dropped in the presence of overexpressed p63RhoGEF 331-580 . A similar trend was also observed on ET-1 stimulation (data not shown). We then asked if p63RhoGEF 331-580 interferes with the RhoA activation pathway by interacting with G␣ q/11 or with endogenous p63RhoGEF. For this experiment, it was necessary to use cells that do not express endogenous p63RhoGEF, and we chose the HEK293 cells, which provide an additional benefit of easy transfection. Therefore, we overexpressed in HEK293 cells p63RhoGEF with and without full-length p63RhoGEF. Due to compet- itive coexpression of full-length p63RhoGEF and p63RhoGEF 331-580 , the expression level of full-length p63RhoGEF was higher when it was expressed alone. Despite this, immunoprecipitation resulted in precipitation of p63RhoGEF only in the presence of full-length p63RhoGEF ( Figure 6B ). This finding is consistent with structural and in vitro studies suggesting that an intramolecular association of the PH domain with the DH domain results in autoinhibition. 45 We then examined whether the p63RhoGEF interacts with G␣ 11 . Full-length p63RhoGEF and p63RhoGEF , both FLAG-tagged, were coexpressed with G␣ q/11 wild-type or constitutively active G ␣11 Q209L mutant in HEK293 cells ( Figure 6C ). As expected, G␣ 11 Q209L showed higher affinity for full-length p63RhoGEF and p63RhoGEF 331-580 than G␣ q/11 wild-type, again, consistent with the in vitro studies showing direct association of activated G␣ q/11 and p63RhoGEF. 45, 49 
Discussion
The RhoA/ROCK pathway serves as a final signaling hub in all SM tissues, accepting stimulatory signals initiated by diverse agonists, and activating Ca 2ϩ -sensitization through inhibition of myosin light chain phosphatase. This physiological phenomenon is of critical significance in control of blood pressure, airway resistance, erectile dysfunction, gut motility, bladder and ureter function, and so forth. 3 The central role of the ROCK kinase prompted a number of investigations into its potential as a drug target. 50 However, the ubiquitous distribution of ROCK reduces the clinical potential of this approach, as it lacks the desired tissue specificity. On the other hand, upstream of ROCK, RhoA appears to be activated through diverse pathways, each utilizing a specific combination of GPCRs, trimeric G-proteins and GEFs. This raises the exciting possibility of selective targeting of tissue-specific GEFs for therapeutic use.
To better understand the intricate nature of the Ca 2ϩ -independent component of contractile stimulation in SM, it is necessary to dissect the molecular pathways and identify the individual GPCRs as well as their partner G-proteins and coupled GEFs. Most vasoconstrictors, such as angiotensin II, ET-1, phenylephrine, and thromboxane A2 bind to GPCRs coupled either to G␣ q/11 or G␣ 12/13 or both. 30 In mice, knockout of G␣ q/11 but not G␣ 12/13 results in a fall in basal blood pressure while both are needed for the development of salt-induced hypertension. Studies of contractility of aorta from these mice showed that phenylephrineinduced force was completely abolished in the G␣ q/11 deficient mice but unaffected in the absence of G␣ 12/13 . On the other hand, contractions in response to ET-1 or U46619 are mediated by both G-proteins, with G␣ q/11 dominating for ET-1 and G␣ 12/13 for U46619. The key question is what portion of Ca 2ϩ -sensitized contractile response is transduced by each of these G-proteins, and if their signaling pathways are routed through distinct GEFs.
Although G␣ 12/13 was shown to activate RhoA through the three RGSL-containing, RhoA-specific GEFs, for example, PDZRhoGEF, LARG, and p115RhoGEF, 24 the pathways involving G␣ q/11 remained unclear. It has been established that the RhoA-specific exchange factor p63RhoGEF is selectively activated by G␣ q/11 . 45, 49, 51 Recently, mRNA transcripts for p63RhoGEF were identified in rat aorta. 52 In an unrelated study, p63RhoGEF coupling through G␣ q/11 has been shown in cultured rat aortic SM cells to mediate angiotensin II signaling. 35 It was found that angiotensin II first induces a rapid influx of intracellular [Ca 2ϩ ] and activation of p63RhoGEF, followed by a significantly slower, [Ca 2ϩ ]/Janus kinase 2-dependent activation of p115RhoGEF to sustain RhoA signaling. However, the role of this pathway in contractility was assessed only by a collagen contraction assay using cultured rat aortic SM cells known to dedifferentiate in culture. As expected, basal contraction increased on angiotensin II pathway stimulation but not in p63RhoGEF depleted cells. 35 The purpose of our investigation was to dissect the specific role of p63RhoGEF-mediated Ca 2ϩ sensitization sensitization of contractile force induced by ET-1 but not by U46619 was significantly reduced when p63RhoGEF expression was suppressed ( Figure 4 ). Furthermore, this was accompanied by a decrease in MYPT1 phosphorylation indicative of decreased RhoA/ROCK activity. These and other findings 30 lead us to suggest that the G ␣q/11 contribution to the regulation of basal and stimulated blood pressure may signal through p63RhoGEF rather than solely through PLC␤-induced Ca 2ϩ release. Consistent with this idea is the observation that ROCK inhibitor Y-27632 reduces hypertension 53, 54 and that the Rho/ROCK signaling pathway in SM cells is an important contributor to peripheral resistance. 55 Significantly, p63RhoGEF mRNA is expressed in the resistance vessels, thoracodorsal and mesenteric arteries (Figure 1 ). P63RhoGEF protein was also detected in these vessels (data not shown). The contribution of this RhoGEF to the contractile behavior of resistance vessels will be explored in the future.
We also wondered if the in vivo mechanism by which p63RhoGEF operates in SM is consistent with a model derived from crystallographic studies of its complex with activated G␣ q/11 . 49 We hypothesized, that if the Ca 2ϩ -sensitization effect is mediated by the same mechanism, then the isolated, recombinant extended PH domain (p63RhoGEF 331-580 ) should interfere with the process, either by binding to the activated G␣ q/11 and blocking downstream signaling, or by binding to the transiently open, for example, active conformation of endogenous p63RhoGEF. To test this hypothesis in blood vessels, we performed contractility assays using ß-escin permeabilized rabbit portal vein to allow introduction of the p63RhoGEF fragment into the SM cells. As expected, p63RhoGEF 331-580 induced relaxation after phenylephrine-induced contraction, which is known to be mediated by G␣ q/11 . 30 This was accompanied by a decrease in RhoA-GTP and phospho-RLC 20 , suggesting suppression of G␣ q/11 -coupled RhoGEF activity. Reduction of RhoA activity on stimulation by phenylephrine in the presence of exogenous p63RhoGEF
331-580 , acting as a dominant negative, was also observed in MEF cells. Overexpressed 331-580 associated with the full-length p63RhoGEF and with activated G␣ q/11 . Our findings are consistent with the DH domain of p63RhoGEF being auto-inhibited through its extended PH domain under basal conditions with agonist activated G␣ q/11 relieving this auto-inhibition as shown in compelling in vitro experiments. 45, 49 A similar fragment of p63RhoGEF, comprising residues 295 to 580, was also shown to interfere with the angiotensin II-mediated RhoA activation pathway in SM cells. 35 Taken together, these data strongly support the notion that the molecular mechanism inferred from the crystallographic studies is representative of the in vivo phenomenon.
In summary, the evidence presented in our report shows that activation of p63RhoGEF by agonists that stimulate receptors coupled to G␣ q/11 leads to Ca 2ϩ sensitization in blood vessels and cultured SM cells. We show that in addition to angiotensin II, 35 both phenylephrine and ET-1 also signal through p63RhoGEF to active RhoA and Ca 2ϩ sensitized force. We conclude that different G␣ q/11 -coupled receptors can signal through p63RhoGEF to contribute to vascular tone and that it is not unique to angiotensin II stimulation. Indeed, angiotensin II plays a major role in hypertension, whereas the tonic discharge of catecholamines by vasoconstricting sympathetic nerves maintains normotensive blood pressure. Further identification of specific RhoGEFs and characterization of their function in SM is a fertile ground for finding new targets that mediate specific functions of normal and diseased SM including the regulation of vascular tone. 
Novelty and Significance
What Is Known?
• The small GTPase RhoA is activated by multiple agonists and significantly contributes to vascular contractility under physiological as well as pathophysiological conditions such as hypertension.
• Multiple GTP exchange factors (GEFs) are expressed in smooth muscle raising the possibility that specific agonists of specific G-protein coupled receptors (GPCRs) may be associated with distinct RhoGEFs.
• Angiotensin II has been shown to signal through G␣ q/11 in cultured smooth muscle cells but the role of other agonists in intact blood vessels is unknown, particularly agonists that regulate basal vascular tone.
What New Information Does This Article Contribute?
• p63RhoGEF is selectively activated by agonists such as ␣-adrenergic and endothelin-1 that signal through G␣ q/11 in blood vessels and maintain normotensive blood pressure.
• Knock down of p63RhoGEF decreases RhoA activity leading to increased myosin phosphatase activity, decreased myosin phosphorylation and decreased force development in blood vessels.
• We demonstrate in vivo that the molecular mechanism of action of p63RhoGEF is consistent with a model derived from crystallographic studies.
• p63RhoGEF is a potential selective therapeutic target for decreasing peripheral resistance and blood pressure.
Multiple agonists signaling through GPCRs activate the RhoA pathway which plays a central role in the regulation of basal tone, peripheral resistance, hypertension and cerebral vasospasm. RhoGEFs function upstream of RhoA, but it is unclear whether the multiple RhoGEFs present in smooth muscle (SM) couple selectively to specific agonists through GPCRs. If so, this would allow for selective therapeutic targeting of specific RhoGEFs in vascular SM. p63RhoGEF selectively coupled G␣ q/11 but not G␣ 12/13 to RhoA activation in blood vessels, mediating the physiologically important Ca 2ϩ sensitization of force induced with G␣ q/11 -coupled agonists. Experiments using a recombinant extended PH domain fragment of p63RhoGEF show that this region serves as an autoinhibitory domain, interfering with the regulatory pathway by sequestering activated G␣ q/11 . Our study extends the reported findings on angiotensin II to other G␣ q/ 11-coupled agonists such as ␣-agonists and endothelin-1. Angiotensin II plays a major role in hypertension while catecholamines maintain normotensive blood pressure. We suggest that signaling through p63RhoGEF contributes to selective regulation of blood pressure. Further identification of specific RhoGEFs and characterization of their function in SM could identify new targets for regulating specific functions of normal and diseased SM.
Supplemental Material
Characterization of anti-p63RhoGEF antibodies
An anti-p63RhoGEF antibody (Proteintech 51004-1-AP) typically gave triplet bands across species (i.e. mouse, rat and rabbit) (Figure 2 ; Online Figure I ; rabbit data is not shown) with an 80 kDa upper band which we propose is a full-length p63RhoGEF based on the following reasons: 1) Exogenously expressed N-terminally FLAG-tagged and C-terminally Myc-tagged full-length p63RhoGEF (580 amino acids) detectable by anti-FLAG and anti-Myc antibodies ran as a single 80 kDa band (Online Figure I, C) .
Over-expressed p63RhoGEF was also detectable by anti-p63RhoGEF antibody and ran as a single 80 kDa band (Online Figure I, B) ; 2) The antibody (Proteintech 51004-1-AP) did not recognize an exogenously expressed 80 kDa protein when a single mutation (L580Q) was introduced in its epitope region (Online Figure I, B) . Therefore the lowest molecular weight band is a non-specific cross-reaction.
The slower electrophoretic mobility of p63RhoGEF running at 80kDa rather than 63kDa is likely a reflection of unique migration properties of residues 503-580 based on the following observations:
N-terminally and C-terminally truncated p63RhoGEF 331-502 comprising mainly the PH domain gave an apparent size of approximately 22 kDa by electrophoresis in agreement with its predicted size of 22.1 kDa.
However, N-terminally truncated p63RhoGEF 331-580 comprising the PH domain and all the residues to its C-terminal end gave an apparent size of approximately 40 kDa whereas its predicted size is 30.3 kDa (data not shown). In other words, addition of residues from 503 to 580 resulted in approximately a 10 kDa upward shift in apparent molecular weight partially accounting for the higher than predicted molecular weight of full-length p63RhoGEF measured by electrophoresis. This slower migration of p63RhoGEF 331-580 was further verified by Western blot analysis using anti-HA and anti-Myc antibodies to detect over-expressed N-terminally HA-tagged and C-terminally Myc-tagged p63RhoGEF 331-580 , resulting in a band slightly higher than 40 kDa (data not shown). Taken together, we concluded that the 80 kDa band corresponds to full-length p63RhoGEF and that its slower than predicted electrophoretic mobility reflects unique migration properties of C-terminal residues 331-580.
Detailed Methods
Antibodies
Rabbit polyclonal anti-G αq/11 antibody (Santa Cruz Biotechnology California sc-392 1:1000); mouse 
Tissue screen
Tissues were isolated from mice, rats and rabbits and outer connective tissue was carefully removed.
Longitudinal SM was isolated from ileum. The cerebral vessels on the ventral surface of the brain were used. This included the posterior inferior cerebral arteries and the contiguous vessels up to and including the circle of Willis. The endothelium was removed from blood vessels, except cerebral vessels, by gently rubbing with a cotton tip. Tissues were homogenized in homogenization buffer (1% SDS, 300 mM NaCl, 50 mM Tris pH 7.5) and cleared by centrifugation at 14,000 x g for 10 min. Protein content of supernatants were measured by Lowry method and equalized for loading. 4X Sample buffer (250 mM Tris pH 6.8, 60% glycerol, 60 mM DTT, 0.016% Bromophenol Blue) was added to 25% of the final volume and samples were subjected to Western blot analysis and the bands were quantitated.
Production of p63RhoGEF 331-580 recombinant protein E. coli BL21 was transformed with pGST-Parallel1-p63RhoGEF 331-580 , pre-cultured to OD 600 2.0 at 37°C
and further cultured at 16°C in Terrific Broth containing 100 mg/l ampicillin for 24 h. Bacteria were harvested by centrifugation, re-suspended in ice-cold PBS containing protease inhibitors (complete protease inhibitor cocktail tablets; Roche) and lysed by French press. Cell lysate was cleared by a two-step centrifugation, first at 20,000 g for 15 min followed by a 65,000 g spin for 1.5 h (both at 4°C). Resulting supernatant was incubated with glutathione sepharose 4 fast flow beads (Amersham) overnight at 4°C.
After thorough wash by PBS, the beads were packed in a column, and GST-p63RhoGEF 331-580 was eluted by 5 mM reduced glutathione in 50 mM Tris (pH 8.0). Cleavage of GST by the Tobacco Etch Virus (TEV) protease was carried out while the eluate was dialyzed against relevant buffer for TEV proteolysis [0.5 mM EDTA, 100 mM NaCl, 5 mM 2-mercaptoethanol, 50 mM Tris (pH 8.0)] overnight at 4°C
followed by dialysis against PBS on the next day. Removal of cleaved GST, uncleaved protein and the TEV protease (polyhistidine-tagged) was done by incubating the sample with the glutathione beads together with Ni-NTA agarose overnight at 4°C.
Smooth muscle contractility measurements
SM strips were cut from freshly isolated blood vessels or from mouse blood vessels following organ culture for silencing p63RhoGEF (described below). SM strips 2 mm long and 200 µm wide were cut with razor knives from blood vessels, attached with monofilament silk to a force transducer at one end and a rigid hook at the other and mounted on a bubble plate as described previously 1 For evaluation of Ca 2+ sensitization in mouse PAMV strips treated with shRNAs, strips were permeabilized with Staphylococcus aureus alpha toxin (60,000 units·ml -1 ·h -1 ) in G1 solution 4 . Treatment with 10 µM A23187 for 10 min was used to deplete Ca 2+ stores. Muscles were contracted by transferring from a G1 solution to pCa6.3. When contraction reached a plateau, the Ca 2+ sensitization pathway was activated by ET-1 (50 and then 100 nM) or U46619 (100nM) plus GTP (1 µM). Once this tension reached a plateau, GTPγS (10 µM) was added to measure the residual component of Ca 2+ sensitizated force. Final maximal tension was elicited by pCa4.5 solution. ET-1-induced force was normalized to maximal pCa4.5
force.
For the experiments in which recombinant p63RhoGEF 331-580 was added to PAMV muscle strips from rabbit, the strips were permeabilized with 50 µM β-escin in relaxing 1 mM EGTA (G1) solution 2, 3 for 30 min. β-escin treatment allows access of the recombinant protein to the cytoplasm. Treatment with 10 µM A23187 for 10 min was used to deplete Ca 2+ stores. Calmodulin (1 µM) was added to all solutions.
Muscles were contracted by transferring from a G1 solution to pCa6.3. When contraction reached a plateau, the Ca 2+ sensitization pathway was activated by phenylephrine (2.5 µM) plus GTP (1 µM). When contraction reached the second plateau, recombinant p63RhoGEF 331-580 protein (40 µM) was added, which relaxed the muscle.
Organ cultured tissues compared to untreated freshly-isolated tissues respond to the same agonists and the relationship of the responses to different agonists is conserved. We have not directly compared maximal contractile activity of freshly isolated with organ cultured mouse vessels. However, the sensitivity settings used for recording tension are the same, so we do not think that contractile activity is depressed by more than 10-20% over 5 days in organ culture. Organ cultured mouse PAMV displayed normal spontaneous rhythmic activity similar to freshly isolated tissue.
Rhotekin assay
Rabbit portal vein strips were prepared and treated (i.e. equilibration, permeabilization, induction of Ca 
RLC 20 and MYPT1 phosphorylation
RLC 20 phosphorylation in rabbit portal vein strips was measured following the same treatment using the same protocol as described above for the Rhotekin assay. Tissues were quick-frozen in 10% trichloroacetic acid in acetone chilled to -80C, at the time points described above for the rhotekin assay.
Quantitation of MYPT1 phosphorylation at Thr853 in mouse portal vein strips was carried out following permeabilization and identical treatment as shown in the SM contractility measurement protocol (Fig.   4A,B) . Tissues samples were rapidly frozen in 10% trichloroacetic acid in acetone chilled to -80C after a 7-minute stimulation by ET-1 (50 nM) or U46619 (150nM). Subsequently, tissue samples were processed as described previously 6 . Briefly, frozen strips were subsequently washed with pure acetone, dried, homogenized in homogenization buffer (1% SDS, 150 mM NaCl, 50 mM Tris pH 7.5), boiled and cleared by centrifugation at 14,000 x g for 10 min. Protein content in each sample was equalized based on the protein concentration measurement by Lowry method. 4X sample buffer (250 mM Tris pH 6.8, 60%
glycerol, 60 mM DTT, 0.016% Bromophenol Blue) was added to 25% of the final volume of the samples.
The samples were subjected to Western blot analysis to detect total RLC 20 , phosphorylated RLC 20 at Ser19, total MYPT1 and MYPT1 phosphorylated at Thr853 using antibodies detailed above. The relative phosphorylation levels were quantitated by normalizing to total RLC 20 or total MYPT1 respectively.
Co-immunoprecipitation assays
FLAG-p63RhoGEF-Full-Myc was expressed by itself or with FLAG-p63RhoGEF 331-580 in HEK293 cells.
The cells were lysed in buffer [0.5% Triton X-100, 150 mM NaCl, 50 mM Tris (pH 7.5), 2 mM EDTA, 2 mM sodium orthovanadate, 50 mM NaF, 1% protease inhibitor cocktail (SIGMA)] and subjected to protein G agarose with anti-Myc antibody. The agarose was washed with lysis buffer and subjected to Western blot analysis using anti-FLAG antibody.
Full-length FLAG-p63RhoGEF-Myc or FLAG-p63RhoGEF 331-580 were co-expressed with G α11 wild-type or G α11 Q209T constitutively active mutant in HEK293 cells. The cells were lysed in buffer [0.5% Triton X-100, 150 mM NaCl, 50 mM Tris (pH 7.5), 2 mM EDTA, 2 mM sodium orthovanadate, 50 mM NaF, 1% protease inhibitor cocktail (SIGMA)] and immunoprecipitation was performed using EZview Red ANTI-FLAG M2 Affinity Gel (SIGMA). The gel was washed with lysis buffer and subjected to Western blot analysis. Portal vein SM strips were isolated from male C57B mice and incubated in 100 ml of OPTIMEM containing adenovirus constructs to express control non-targeting shRNA or the shRNA sequence targeting p63RhoGEF mRNA at 1x10^10 PFU. After 24 h, 100 ml of serum free media containing additional adenovirus at 1x10^10 PFU was added and this was repeated one more time. 
